The FDA accepted the resubmission of the RP1 Biologics License Application for advanced melanoma, with a decision expected by August 2026. This regulatory milestone signals significant progress toward potential approval for this combination therapy.
The FDA accepted the resubmission of the RP1 Biologics License Application for advanced melanoma, with a decision expected by August 2026. This regulatory milestone signals significant progress toward potential approval for this combination therapy.